Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting
Treatment with Selinexor Prolongs Progression-Free Survival Compared to Placebo (5.5 months versus 2.7 months, respectively) in Patients with Liposarcoma Additional Selinexor Data Posters from Investigator-Sponsored Trials Show Early Signals of Activity …